The estimated Net Worth of James E Fickenscher is at least $1.34 Milione dollars as of 12 September 2023. Mr. Fickenscher owns over 8,998 units of Zynerba Pharmaceuticals Inc stock worth over $491,513 and over the last 10 years he sold ZYNE stock worth over $29,243. In addition, he makes $824,107 as Chief Financial Officer e Vice President - Corporate Development at Zynerba Pharmaceuticals Inc.
Sign up
Mr. Fickenscher ZYNE stock SEC Form 4 insiders trading
James has made over 8 trades of the Zynerba Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 8,998 units of ZYNE stock worth $11,967 on 12 September 2023.
The largest trade he's ever made was buying 135,000 units of Zynerba Pharmaceuticals Inc stock on 18 March 2016 worth over $97,200. On average, James trades about 10,386 units every 145 days since 2014. As of 12 September 2023 he still owns at least 378,087 units of Zynerba Pharmaceuticals Inc stock.
You can see the complete history of Mr. Fickenscher stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Fickenscher biography
James E. Fickenscher CPA serves as Chief Financial Officer, Vice President - Corporate Development of the Company. Mr. Fickenscher has more than 30 years of financial, business development and executive leadership experience in the pharmaceutical industry. Prior to joining our company, he served as the senior vice president, chief financial officer of Antares Pharma, Inc., a specialty pharmaceutical company, from November 2014 to September 2016. Previously, Mr. Fickenscher served as chief financial officer of Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, from May 2005 until August 2014. From January 2000 until April 2004, Mr. Fickenscher served as senior vice president chief financial officer of Aventis Behring L.L.C., a wholly owned subsidiary of Aventis, predecessor to Sanofi S.A. Mr. Fickenscher joined Aventis Behring L.L.C. in 1995 as vice president, business development and strategic planning and, from that time until 2000, also held the positions of general manager, Japan and vice president & general manager, Hemophilia Business Unit. Throughout his tenure at Aventis Behring L.L.C, he was also responsible for strategic planning. Prior to Aventis Behring L.L.C, Mr. Fickenscher worked at Rhone-Poulenc Rorer, predecessor to Sanofi S.A., in its Collegeville, PA and Paris, France offices and at Deloitte & Touche LLP. Mr. Fickenscher received his B.S. at Bloomsburg University of Pennsylvania. He is a member of the American Institute of Certified Public Accountants.
What is the salary of James Fickenscher?
As the Chief Financial Officer e Vice President - Corporate Development of Zynerba Pharmaceuticals Inc, the total compensation of James Fickenscher at Zynerba Pharmaceuticals Inc is $824,107. There are 3 executives at Zynerba Pharmaceuticals Inc getting paid more, with Armando Anido having the highest compensation of $1,369,570.
How old is James Fickenscher?
James Fickenscher is 56, he's been the Chief Financial Officer e Vice President - Corporate Development of Zynerba Pharmaceuticals Inc since 2018. There are 11 older and 3 younger executives at Zynerba Pharmaceuticals Inc. The oldest executive at Zynerba Pharmaceuticals Inc is Daniel Kisner, 72, who is the Independent Director.
What's James Fickenscher's mailing address?
James's mailing address filed with the SEC is C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON, PA, 19333.
Insiders trading at Zynerba Pharmaceuticals Inc
Over the last 9 years, insiders at Zynerba Pharmaceuticals Inc have traded over $154,101 worth of Zynerba Pharmaceuticals Inc stock and bought 224,703 units worth $2,383,877 . The most active insiders traders include John P. Butler, William J Federici e Michael Rapp. On average, Zynerba Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $12,515. The most recent stock trade was executed by Terri B Sebree on 12 September 2023, trading 12,401 units of ZYNE stock currently worth $16,493.
What does Zynerba Pharmaceuticals Inc do?
at zynerba pharmaceuticals (nasdaq: zyne), we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain through these therapeutics. our development pipeline includes patent-protected synthetic transdermal cannabinoid products, cbd gel – zyn002 and thc pro-drug patch – zyn001, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.
What does Zynerba Pharmaceuticals Inc's logo look like?
Complete history of Mr. Fickenscher stock trades at Antares Pharma Inc e Zynerba Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc executives and stock owners
Zynerba Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Armando Anido,
Chairman of the Board, Chief Executive Officer -
Terri Sebree,
President -
Armando Anido MBA,
Chairman & CEO -
James Fickenscher,
Chief Financial Officer, Vice President - Corporate Development -
Terri B. Sebree,
Pres -
James E. Fickenscher,
CFO, VP of Corp. Devel. & Treasurer -
Suzanne Hanlon,
Vice President, General Counsel, Secretary -
William Roberts,
Vice President, Investor Relations and Corporate Communications -
Pamela Stephenson,
Independent Director -
Kenneth Moch,
Independent Director -
Daniel Kisner,
Independent Director -
William Federici,
Independent Director -
John Butler,
Independent Director -
Warren Cooper,
Lead Independent Director -
Brian Rosenberger,
Vice President - Commercial and Business Development -
Joseph Apostolico,
VP of HR -
Suzanne M. Hanlon,
Sec., VP & Gen. Counsel -
Dr. Joseph Palumbo,
Chief Medical Officer -
Thomas L Harrison,
Director -
Michael Rapp,
10% owner -
Cynthia Ann Rask,
Director -
Albert P Parker,
Chief Legal Officer -
Richard A Baron,
Chief Financial Officer -
Kenneth T Jones,
See Remarks